Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma
0 Views
administrator
07/17/23
Dr Kaufman speaks with ecancertv at ASCO 2016 to discuss the results of phase II JAVELIN Merkel 200 trial, in which patients with metastatic Merkl cell carcinoma received avelumab, a PD-L1 checkpoint inhibitor.
Merkel cell carcinoma (MCC) is an aggressive skin cancer associated with Merkel cell polyomavirus, with limited therapeutic options after 1st-line chemotherapy.
Dr Kaufman describes the results of the JAVELIN trial in which, of a cohort of 88, six patients (9.8%) achieved complete responses, 12 (19.7%) had partial responses, and 7 (11.5%) had stable disease (83.3% responses were ongoing).
He also details the ongoing progression free survival data, and offers that additional clinical evaluation of avelumab for is warranted.
-
Category
Show more
Facebook Comments
No comments found